Last reviewed · How we verify
Lusedra (FOSPROPOFOL)
Lusedra (FOSPROPOFOL) is a small molecule drug that targets the GABA-A receptor, classified as a fospropofol. It was originally developed and is currently owned by a pharmaceutical company. Lusedra is FDA-approved for sedation as an adjunct to anesthesia and was approved in 2008. It is off-patent, meaning there are no active Orange Book patents, and there are no generic manufacturers. As an off-patent drug, its commercial status is subject to change.
At a glance
| Generic name | FOSPROPOFOL |
|---|---|
| Drug class | fospropofol |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
- Sedation as Adjunct to Anesthesia
Common side effects
Key clinical trials
- Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia
- Fospropofol Disodium ED95 for Elderly Spinal Anesthesia Sedation (PHASE4)
- Effect of Remifentanil on Pruritus and Paresthesia of Fospropofol Disodium Anesthesia (NA)
- Clinical Study of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment (NA)
- ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia (PHASE4)
- Efficacy and Safety of Fospropofol in Adult Laparoscopic Surgery: A Clinical Trial (PHASE4)
- Safety and Efficacy of Fospropofol vs Propofol During Invasive Mechanical Ventilation. (NA)
- Efficacy and Safety of Fospropofol for Same-day Bidirectional Endoscopy in Elderly Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lusedra CI brief — competitive landscape report
- Lusedra updates RSS · CI watch RSS